Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
Jung Min Lee(Kyung Hee University), Elise C. Kohn(National Cancer Institute), Nicole Houston(Johns Hopkins University), Cody J. Peer(National Institutes of Health), Liang Cao(National Institutes of Health), Christina M. Annunziata(National Cancer Institute), Jeffers Nguyen(Johns Hopkins University), Janis M. Taube(Bloomberg (United States)), Elizabeth Thompson(University of Pennsylvania), Ashley Cimino‐Mathews(Bloomberg (United States)), Tony W. Ho(Johns Hopkins University), Stanley Lipkowitz(Center for Cancer Research), Aleksandra Ogurtsova(Johns Hopkins University), Dana‐Adriana Botesteanu(Johns Hopkins University), Alexandra S. Zimmer(Johns Hopkins University), William D. Figg(National Cancer Institute), Elizabeth M. Swisher(University of Washington), Haiying Xu(Johns Hopkins University), Maria I. Harrell(Johns Hopkins University)
Cited by 241
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k